A study to find out how safe is it to give people with asthma a new medicine called MTPS9579A
Respiratory Disorder Asthma
Basic Details
People with asthma requiring inhaled corticosteroids and a second controller were enrolled at six study sites in one country to evaluate the safety and tolerability of MTPS9579A, an antibody drug against tryptase. Twenty-seven participants completed the study and comprised the safety-evaluable population. This was a Phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study. Results showed MTPS9579A to be tolerable with no drug-related serious side effects or drug-related non-serious side effects. The Sponsor is no longer developing MTPS9579A for asthma. This decision had nothing to do with the safety of the medicine.
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
For the latest version of this information please go to www.forpatients.roche.com